Trump's CMS signals flexibility on Medicare drug price negotiation, sparking new questions for RFK Jr.
The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input f | The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program.
Medicare targets 15 more drugs for price negotiations — including Ozempic
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
The talks around drugs including Novo Nordisk’s Wegovy, GSK’s Trelegy Ellipta, and Pfizer’s Xtandi will set Medicare prices that go into effect in 2027.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Trump order signals shake-up in drug pricing innovation through Medicare and Medicaid
Biden-era policies rescinded by Donald Trump could signal a significant shake-up in Medicare and Medicaid drug price reforms.
US govt looks to bring 'greater transparency' in Medicare drug price negotiations
The U.S. government said on Wednesday it will consider opportunities to "bring greater transparency" for the Medicare drug price negotiation program under President Donald Trump's administration. The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.
Trump's Administration Aims for 'Greater Transparency' in Drug Price Negotiations
The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under President Donald Trump's administration following criticism from the pharmaceutical industry for the Biden-era law.
Trump administration affirms drug price talks, but will seek input to ‘improve’ program
A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more transparent.
Creative Counting Can’t Fix The Inflation Reduction Act's Flaws
Millions of Part D patients who rely on price-controlled drugs will see their out-of-pocket medication costs increase.
Fact Check: Insulin cap for Medicare unaffected by Trump order on prescription drug costs
A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe ...
Here Are 7 Medicare Changes for 2025 That You Should Know About
Medicare is big business, recently providing healthcare coverage to 68 million people. It changes a little or a lot every ...
How Medicare Part D Has Changed for 2025
The Inflation Reduction Act of 2022 has triggered a raft of changes to Medicare Part D plans and Medicare Advantage plans that affect prescription drug coverage in 2025. Here’s what to know.
No, Trump did not get rid of Medicare’s $35 insulin cap
Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly ...